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The human C3b/C4b receptor, termed CRI, is present on erythrocytes,
monocytes/macrophages, granulocytes, B cells, some T cells, splenic follicular
dendritic cells, and glomerular podocytes (1-5). A soluble form of the receptor
has been found in plasma that has ligand binding activity and the same Mr as
membrane-associated CRI (6). CRI binds C3b and C4b that have covalently
attached to immune complexes and other complement activators, and the con-
sequences of these interactions depend upon the cell type bearing the receptor
(7). Erythrocyte CRI binds immune complexes for transport to the liver (8, 9).
CR1 on neutrophils and monocytes internalizes bound complexes, either by
adsorptive endocytosis through coated pits (10, 11) or by phagocytosis after
activation of the receptor by phorbol esters, chemotactic peptides, or proteins
that are present in the extracellular matrix, such as fibronectin and laminin (12-
14). Phosphorylation of CRI may have a role in the acquisition of phagocytic
activity. The function of CRI on B lymphocytes is less defined, although
treatment of these cells with antibody to CR1 enhanced their response to
suboptimal doses of PWM (15). CRI on follicular dendritic cells may subserve
an antigen presentation role (16) and the function ofCRI on Tcells is unknown.
CRI can also inhibit the classical and alternative pathwayC3/C5 convertases and
act as a cofactor for the cleavage of C3b and C4b by factor I, indicating that
CRI alsohas complement regulatory functions inaddition to servingasareceptor
(17, 18).
CRI is a glycoprotein composed of a single polypeptide chain. An unusual
structure for the receptor was first suggested by the finding of four allotypic
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forms differing by increments of ^-40,000-50,000 Mr. The two most common
forms, the F and S allotypes, also termed the A and B allotypes, have M,. of
250,000 and 290,000 (19, 20), respectively, and two rarer forms have M, of
210,000 and >290,000 (21, 22). These differences apparently represent varia-
tions in the polypeptide chain of CRI because they were not abolished by
treatment of purified receptor protein with endoglycosidase F (20) and they were
observed when receptor allotypes were biosynthesized in the presence of tuni-
camycin (23). All four CR1 allotypes have Cab-binding activity, indicating that
insertion or deletion of these relatively large peptide segments does not destroy
the ligand binding site (19-22).
Additional evidence for an unusual structure for CRI was the findingthat two
nonoverlapping restriction fragments of a CRI cDNA crosshybridized under
conditions of high stringency (24). This indication ofrepetitive coding sequences
was supported by the observation that both cDNA probes hybridized to multiple
restriction fragments of genomic DNA, most of which were common to both
probes (24). In addition, the CR1 gene hasbeen shown recently to have repetitive
intervening sequences by the demonstration of crosshybridization of a genomic
probe lacking coding sequences to several genomic restriction fragments (25).
Further, DNA from an individual having the larger S allotype had an additional
restriction fragment hybridizing to this genomic probe when compared with
DNA from an individual having the F allotype, suggesting that duplication of
genomic sequences occurred in association with the higher molecular weight
CRI allele (25).
In thepresent study, the repetitive unit of CRI was defined by sequencing 5.5
kb of tonsillar CRI cDNA. Three tandem, direct repeats of 1.35 kb were found
that encode 50-kD peptide segments, termed long homologous repeats (LHR).'
Each LHR is composed of seven short consensus repeats (SCR) that are charac-
teristic of C3/C4 binding proteins.
Materials and Methods
Isolation and Sequence of CRI Tryptic Peptides.
￿
CRI was purified from washed human
erythrocyte membranes by sequential Matrex Red A and YZ-I mAb affinity chromatog-
raphy (26). Tryptic peptides were prepared and isolated by sequential gradient and
isocratic reverse-phase HPLC as described (24). Tryptic peptide analysis was performed
with a 470A Protein Sequencer (Applied Biosystems, Inc., Foster City, CA), andanalysis
of each degradative cycle was achieved using a 120 PTH-amino acid analyzer (Applied
Biosystems, Inc.).
Isolation ofcDNA Clones and Genomic Clones.
￿
AcDNA librarywasconstructed in Xgtl l
from human tonsillar poly(A)' RNA as described (24). By RNA blot hybridization, the
tonsil donor was homozygous for the F allele of CR1 (24). The cDNA was selected on an
agarose gel to include fractions between 2 and 7 kb before the cloning steps. The initial
complexity of the library was 4.5 X 106 recombinants per 100 ng cDNA and the library
was amplified in Escherichia coli strain Y1088. The library was screened (27) with CRI
probes, CRI-I and CRI-2 (24), that had been radiolabeled to a sp act of 2-8 X 108
cpm/ug by nick translation. Hybridization was performed in 50% formamide, 5X SSC
(IX SSC: 15 mM sodium citrate, 150 mM sodium chloride) at 43 °C and filters were
washed at 60 °C in 0.2X SSC, conditions that do not allow the detection of CR2 cDNA
'Abbreviations used in thispaper:
￿
C46p, C4-binding protein; LHR, long homologous repeat; SCR,
shortconsensusrepeat.5'
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Restriction map of 5.5 kb of human CR1 cDNA . The black bar indicates the
cDNA, restriction sites are H, Hind III ; B, Bam HI ; R, Eco RI ; P, Pst I ; A, Apa I ; S, Sac I ; G,
Bg1 II ; K, Kpn I . The cDNA clones from which the sequence was derived are shown below
the map . The arrows indicate the direction and extent ofsequence analysis by the dideoxynu-
cleotide chain termination method . cDNA clones were oriented on the basis of restriction
maps and overlapping sequence identity . The grey portion of clone T9.4 indicates that this
sequence was determined to be an unspliced intervening sequence as described in the text.
clones (28) . Positive clones were plaque-purified twice before restriction mapping and
DNA sequence analysis.
A genomic library was constructed in EMBL-3 with 15-20-kb fragments produced by
partial digestion of human leukocyte DNA with Sam 3AI . The initial complexity was 1 .2
x 106 and the library was amplified in E. coli strain P2392 . The library was also screened
with the cDNA probes CR1-1 and CR1-2 (24) .
DNA Sequence Analysis.
￿
Restriction fragments of the cDNA clones were subcloned in
M13mp18 or M13mpl9 and sequenced by the dideoxynucleotide chain termination
method (29) . Some clones were sequenced in whole or in part by first creating ordered
deletion mutants using exonuclease III (30) . Each region was sequenced on both strands
and in most cases each region was sequenced on M13 subclones constructed from two
independently isolated cDNA clones (Fig . 1) . Sequence data were analyzed with the
University of Wisconsin Genetics Computer Group package (Madison, WI) .
A size-selected tonsillar cDNA library was screened with the CR1-1 and CR1-
2 probes obtained from the CR1 cDNA clone, XT8 .3 (24) . 15 positive phage
were identified out of 1 .5 x 1,06 recombinants and 13 of these represented
distinct clones . 10 were restriction mapped and sequenced in whole or in part
by the dideoxynucleotide chain termination method. The cDNA clones were
aligned on the basis of overlapping sequence identity (Fig. 1) and were found to
span 5.5 kb (Fig. 2) . A single long open reading frame was identified beginningFIGURE 2 .
1098
1 CCAAGTTGAAAACCCAAACCAATGCATCTGACTTTCCCATTGGGACATCTTTAAAGTACG 60
61 AATGCCGTCCTGAGTACTACGGGAGGCCATTCTCTATCACATGTCTAGATAACCTGGTCT 120
121 GGTCAAGTCCCAAAGATGTCTGTAAACGTAAATCATGTAAAACTCCTCCAGATCCAGTGA 180
181 ATGGCATGGTGCATGTGATCACAGACATCCAGGTTGGATCCAGAATCAACTATTCTTGTA 240
241 CTACAGGGCACCGACTCATTGGTCACTCATCTGCTGAATGTATCCTCTCGGGCAATGCTG 300
301 CCCATTGGAGCACGAAGCCGCCAATTTGTCAACGAATTCCTTGTGGGCTACCCCCCACCA 360
361 TCGCCAATGGAGATTTCATTAGCACCAACAGAGAGAATTTTCACTATGGATCAGTGGTGA 420
421 CCTACCGCTGCAATCCTGGAAGCGGAGGGAGAAAGGTGTTTGAGCTTGTGGGTGAGCCCT 480
481 CCATATACTGCACCAGCAATGACGATCAAGTGGGCATCTGGAGCGGCCCGGCCCCTCAGT 540
541 GCATTATACCTAACAAATGCACGCCTCCAAATGTGGAAAATGGAATATTGGTATCTGACA 600
601 ACAGAAGCTTATTTTCCTTAAATGAAGTTGTGGAGTTTAGGTGTCAGCCTGGCTTTGTCA 660
661 TGAAAGGACCCCGCCGTGTGAAGTGCCAGGCCCTGAACAAATGGGAGCCGGAGCTACCAA 720
721 GCTGCTCCAGGGTATGTCAGCCACCTCCAGATGTCCTGCATGCTGAGCGTACCCAAAGGG 780
781 ACAAGGACAACTTTTCACCCGGGCAGGAAGTGTTCTACAGCTGTGAGCCCGGCTATGACC 840
841 TCAGAGGGGCTGCGTCTATGCGCTGCACACCCCAGGGAGACTGGAGCCCTGCAGCCCCCA 900
901 CATGTGAAGTGAAATCCTG+GATGACTTCATGGGCCAACTTCTTAATGGCCGTGTGCTAT 960
961 TTCCAGTAAATCTCCAGCTTGGAGCAAAAGTGGATTTTGTTTGTGATGAAGGATTTCAAT 1020
1021 TAAAAGGCAGCTCTGCTAG+TATTGTGTCTTGGCTGGAATGGAAAGCCTTTGGAATAGCA 1080
1081 GTGTTCCAGTGTGTGAACAAATCTTTTGTCCAAGTCCTCCAGTTATTCCTAATGGGAGAC 1140
1141 ACACAGGAAAACCTCTGGAAGTCTTTCCCTTTGGAAAAGCAGTAAATTACACATGCGACC 1200
1201 CCCACCCAGACAGAGGGACGAGCTTCGACCTCATTGGAGAGAGCACCATCCGCTGCACAA 1260
1261 GTGACCCTCAAGGGAATGGGGTTTGGAGCAGCCCTGCCCCTCGCTGTGGAATTCTGGGTC 1320
1321 ACTGTCAAGCCCCAGATCATTTTCTGTTTGCCAAGTTGAAAACCCAAACCAATGCATCTG 1380
1381 ACTTTCCCATTGGGACATCTTTAAAGTACGAATGCCGTCCTGAGTACTACGGGAGGCCAT 1440
1441 TCTCTATCACATGTCTAGATAACCTGGTCTGGTCAAGTCCCAAAGATGTCTGTAAACGTA 1500
1501 AATCATGTAAAACTCCTCCAGATCCAGTGAATGGCATGGTGCATGTGATCACAGACATCC 1560
1561 AGGTTGGATCCAGAATCAACTATTCTTGTACTACAGGGCACCGACTCAT+GGTCACTCA+ 1620
1621 CTGCTGAATGTATCCTCTCAGGCAATACTGCCCATTGGAGCACGAAGCCGCCAATTTGTC 1680
1681 AACGAATTCCTTGTGGGCTACCCCCAACCATCGCCAATGGAGATTTCATTAGCACCAACA 1740
1741 GAGAGAATTTTCACTATGGATCAGTGGTGACCTACCGCTGCAATCTTGGAAGCAGAGGGA 1800
1801 GAAAGGTGTTTGAGCTTGTGGGTGAGCCCTCCATATACTGCACCAGCAATGACGATCAAG 1860
1861 TGGGCATCTGGAGCGGCCCCGCCCCTCAGTGCATTATACCTAACAAATGCACGCCTCCAA 1920
1921 ATGTGGAAAATGGAATATTGGTATCTGACAACAGAAGCTTATTTTCCTTAAATGAAGTTG 1980
1981 TGGAGTTTAGGTGTCAGCCTGGCTTTGTCATGAAAGGACCCCGCCGTGTGAAGTGCCAGG 2040
2041 CCCTGAACAAATGGGAGCCAGAGTTACCAAGCTGCTCCAGGGTGTGTCAGCCGCCTCCAG 2100
2101 AAATCCTGCATGGTGAGCATACCCCAAGCCATCAGGACAACTTTTCACCTGGGCAGGAAG 2160
2161 TGTTCTACAGCTGTGAGCCTGGCTATGACCTCAGAGGGGCTGCGTCTCTGCACTGCACAC 2220
2221 CCCAGGGAGACTGGAGCCCTGAAGCCCCGAGATGTGCAGTGAAATCCTGTGATGACTTCT 2280
2281 TGGGTCAACTCCCTCATGGCCGTGTGCTATTTCCACTTAATCTCCAGCTTGGGGCAAAGG 2340
2341 TGTCCTTTGTCTGTGATGAAGGGTTTCGCTTAAAGGGCAGTTCCGTTAGTCATTGTGTCT 2400
2401 TGGTTGGAATGAGAAGCCTTTGGAATAACAGTGTTCCTGTGTGTGAACATATCTTTTGTC 2460
2461 CAAATCCTCCAGCTATCCTTAATGGGAGACACACAGGAACTCCCTCTGGAGATATTCCCT 2520
2521 ATGGAAAAGAAATATCTTACACATGTGACCCCCACCCAGACAGAGGGATGACCTTCAACC 2580
2581 TCATTGGGGAGAGCACCATCCGCTGCACAAGTGACCCTCATGGGAATGGGGTTTGGAGCA 2640
2641 GCCCTGCCCCTCGCTGTGAACTTTCTGTTCGTGCTGGTCACTGTAAAACCCCAGAGCAGT 2700
GTGCGTAAACTTGCGTTGGATCTTTCCCATGTCTGCAAAAGCTTCTTATGGAATTATTTC
AAATGTGGGATATGAGAAACCTTTTCTGAAAAGTGTTCGGATAGATGGATFIGURE 2 .
￿
Nucleotide sequence of 5.5 kb of human CR1 cDNA. The strand corresponding
to the mRNA is shown and base number 1 is the first base after the Eco R1 linker in themost
5' clone. The stop codon is underlined . The 110-bp sequence in the box was found between
nucleotides 147 and 148 (arrow) and is believed to represent a portion of an intervening
sequence as described in the text.
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2701 TTCCATTTGCCAGTCCTACGATCCCAATTAATGACTTTGAGTTTCCAGTCGGGACATCTT 2760
2761 TGAATTATGAATGCCGTCCTGGGTATTTTGGGAAAATGTTCTCTATCTCCTGCCTAGAAA 2820
2821 ACTTGGTCTGGTCAAGTGTTGAAGACAACTGTAGACGAAAATCATGTGGACCTCCACCAG 2880
2881 AACCCTTCAATGGAATGGTGCATATAAACACAGATACACAGTTTGGATCAACAGTTAATT 2940
2941 ATTCTTGTAATGAAGGGTTTCGACTCATTGGTTCCCCATCTACTACTTGTCTCGTCTCAG 3000
3001 GCAATAATGTCACATGGGATAAGAAGGCACCTATTTGTGAGATCATATCTTGTGAGCCAC 3060
3061 CTCCAACCATATCCAATGGAGACTTCTACAGCAACAATAGAACATCTTTTCACAATGGAA 3120
3121 CGGTGGTAACTTACCAGTGCCACACTGGACCAGATGGAGAACAGCTGTTTGAGCTTGTGG 3180
3181 GAGAACGGTCAATATATTGCACCAGCAAAGATGATCAAGTTGGTGTTTGGAGCAGCCCTC 3240
3241 CCCCTCGGTGTATTTCTACTAATAAATGCACAGCTCCAGAAGTTGAAAATGCAATTAGAG 3300
3301 TACCAGGAAACAGGAGTTTCTTTTCCCTCACTGAGATCATCAGATTTAGATGTCAGCCCG 3360
3361 GGTTTGTCATGGTAGGGTCCCACACTGTGCAGTGCCAGACCAATGGCAGATGGGGGCCCA 3420
3421 AGCTGCCACACTGCTCCAGGGTGTGTCAGCCGCCTCCAGAAATCCTGCATGGTGAGCATA 3480
3481 CCCTAAGCCATCAGGACAACTTTTCACCTGGGCAGGAAGTGTTCTACAGCTGTGAGCCCA 3540
3541 GCTATGACCTCAGAGGGGCTGCGTCTCTGCACTGCACGCCCCAGGGAGACTGGAGCCCTG 3600
3601 AAGCCCCTAGATGTACAGTGAAATCCTGTGATGACTTCCTGGGCCAACTCCCTCATGGCC 3660
3661 GTGTGCTACTTCCACTTAATCTCCAGCTTGGGGCAAAGGTGTCCTTTGTTTGCGATGAAG 3720
3721 GGTTCCGATTAAAAGGCAGGTCTGCTAGTCATTGTGTCTTGGCTGGAATGAAAGCCCTTT 3780
3781 GGAATAGCAGTGTTCCAGTGTGTGAACAAATCTTTTGTCCAAATCCTCCAGCTATCCTTA 3840
3841 ATGGGAGACACACAGGAACTCCCTTTGGAGATATTCCCTATGGAAAAGAAATATCTTACG 3900
3901 CATGCGACACCCACCCAGACAGAGGGATGACCTTCAACCTCATTGGGGAGAGCTCCATCC 3960
3961 GCTGCACAAGTGACCCTCAAGGGAATGGGGTTTGGAGCAGCCCTGCCCCTCGCTGTGAAC 4020
4021 TTTCTGTTCCTGCTGCCTGCCCACATCCACCCAAGATCCAAAACGGGCATTACATTGGAG 4080
4081 GACACGTATCTCTATATCTTCCTGGGATGACAATCAGCTACACTTGTGACCCCGGCTACC 4140
4141 TGTTAGTGGGAAAGGGCTTCATTTTCTGTACAGACCAGGGAATCTGGAGCCAATTGGATC 4200
4201 ATTATTGCAAAGAAGTAAATTGTAGCTTCCCACTGTTTATGAATGGAATCTCGAAGGAGT 4260
4261 TAGAAATGAAAAAAGTATATCACTATGGAGATTATGTGACTTTGAAGTGTGAAGATGGGT 4320
4321 ATACTCTGGAAGGCAGTCCCTGGAGCCAGTGCCAGGCGGATGACAGATGGGACCCTCCTC 4380
4381 TGGCCAAATGTACCTCTCGTGCACATGATGCTCTCATAGTTGGCACTTTATCTGGTACGA 4440
4441 TCTTCTTTATTTTACTCATCATTTTCCTCTCTTGGATAATTCTAAAGCACAGAAAAGGCA 4500
4501 ATAATGCACATGAAAACCCTAAAGAAGTGGCTATCCATTTACATTCTCAAGGAGGCAGCA 4560
4561 GCGTTCATCCCCGAACTCTGCAAACAAATGAAGAAAATAGCAGGGTCCTTCCTlaaCAAA 4620
4621 GTACTATACAGCTGAAGAACATCTCGAATACAATTTTGGTGGGAAAGGAGCCAATTGATT 4680
4681 TCAACAGAATCAGATCTGAGCTTCATAAAGTCTTTGAAGTGACTTCACAGAGACGCAGAC 4740
4741 ATGTGCACTTGAAGATGCTGCCCCTTCCCTGGTACCTAGCAAAGCTCCTGCCTCTTTGTG 4800
4801 TGCGTCACTGTGAAACCCCCACCCTTCTGCCTCGTGCTAAACGCACACAGTATCTAGTCA 4860
4861 GGGGAAAAGACTGCATTTAGGAGATAGAAAATAGTTTGGATTACTTAAAGGAATAAGGTG 4920
4921 TTGCCTGGAATTTCTGGTTTGTAAGGTGGTCACTGTTCTTTTTTAAAATATTTGTAATAT 4980
4981 GGAATGGGCTCAGTAAGAAGAGCTTGGAAAATGCAGAAAGTTATGAAAAATAAGTCACTT 5040
5041 ATAATTATGCTACCTACTGATAACCACTCCTAATATTTTGATTCATTTTCTGCCTATCTT 5100
5101 CTTTCACATATGTGTTTTTTTACATACGTACTTTTCCCCCCTTAGTTTGTTTCCTTTTAT 5160
5161 TTTATAGAGCAGAACCCTAGTCTTTTAAACAGTTTAGAGTGAAATATATGCTATATCAGT 5220
5221 TTTTACTTTCTCTAGGGAGAAAAATTAATTTACTAGAAAGGCATGAAATGATCATGGGAA 5280
5281 GAGTGGTTAAGACTACTGAAGAGAAATATTTGGAAAATAAGATTTCGATATCTTCTTTTT 5340
5341 TTTTGAGATGGAGTCTGGCTCTGTCTCCCAGGCTGGAGTGCAGTGGCGTAATCTCGGCTC 5400
5401 ACTGCAACGTCCGCCTCCCG 54201100
￿
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at the 5' end of the cDNA clones and extending 4.7 kb downstream to a stop
codon. The coding sequence for CR 1 in this library is expected to be 6 kb, based
on an estimated 220,000 M,. for the nonglycosylated receptor (20). Thus, these
clones span -80% of the estimated coding sequence .
Clones T49.1 and T55.1 contain coding sequence at their 5' ends, indicating
that additional 5' coding and noncoding sequences remain to be identified. In
the 3' region, the overlapping clones, T8.2, T43 .1 and T87.1, contain the
transmembrane and cytoplasmic regions encoded by an identical sequence in
each clone. The clone extending most 3', T8.2, contains 807 by of untranslated
sequence without a poly(A) sequence. Clone T8 .3 contains a 91-bp deletion of
nucleotides 1,406-1,497 and clone T40.1 contains a 9-bp deletion of nucleotides
1,498-1,507 relative to the sequences found in clones T6.1 and T55.1 . These
deletions occurred in regions having sequences homologous to 5' splice sites and
may represent splicing errors in the mRNA. Clones T49 .1 and T55.1 contain a
110-bp insertion between nucleotides 147 and 148 of the open reading frame
(Fig. 2). This sequence is judged to be a portion of an intron because it did not
hybridize to blots of tonsillar poly(A)+ RNA, it contains a 5' splice site (31) (Fig.
2), it is flanked by cDNA sequences in CR1 genomic clones, and it shifts the
reading frame. Clone T9.4 contains 0 .88 kb of intervening sequence at the 3'
end that does not hybridize to blots of tonsillar poly(A)+ RNA (data not shown).
Dot matrix analysis of the nucleotide sequence revealed two types of internal
homologies (Fig. 3). The first is represented by the bold, uninterrupted lines
that indicate the presence of three tandem, direct, highly homologous repeats of
1 .35 kb. These nucleotide sequences encode the LHRs of CRi . The second type
of repeat is represented by the dashed parallel lines that indicate regions of lesser
homology. These sequences occur every 190-210 nucleotides and encode the
SCRs of CR1 .
The amino acid sequence deduced from the cDNA sequence is presented in
Fig. 4 and the three LHRs, designated LHR-B, LHR-C, and LHR-D, are aligned
to demonstrate their homology. LHR-B extends from residue 1 through residue
438, LHR-C corresponds to residues 439-891, and LHR-D extends from residue
892 through 1,341 . Residues 451-694 of LHR-C are 99% identical to residues
1-244 of LHR-B, but only 61 % identical to the corresponding residues of LHR-
D. In contrast, residues 695-891 of LHR-C are 91 % identical to residues 1,148-
1,341 of LHR-D but only 76% identical to the corresponding region of LHR-B.
Thus, LHR-C appears to be a hybrid that comprises sequences most homologous
to the first halfof LHR-B and the second halfof LHR-D. The LHRs are followed
by two SCRs that are not repeated, a 25 residue hydrophobic segment and a 43
amino acid C001-1-terminal region with no sequence homology to the SCRs
(Fig. 4) .
The uncloned 1 .3 kb of the expected 6 kb of coding sequence is considered
to represent a fourth LHR, LHR-A, based on analysis of tryptic peptides of
erythrocyte CR1 . 10 tryptic peptides have sequences identical to the amino acid
sequences derived from the cDNA clones (Table I). In contrast, the sequences
of three tryptic peptides are homologous to, but not identical with, the derived
amino acid sequences from LHR-B, -C and -D (Table 11). Tryptic peptide 56b
differs from the homologous sequence in LHR-B and -C by one residue andKLICKSTEIN ET AL .
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FIGURE 3 .
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Dot matrix analysis of the nucleotide sequence of 5.5 kb of human CR1 cDNA .
A dot was plotted if there was at least a 40 by of 90 by match . The dark line bisecting the
square diagonally indicates the identity of the sequence with itself. Thetwo additional parallel
dark lines 1.35 and 2.7 kb from the line of identity represent two tandem, direct, LHRs of
1.35 kb each . The six lighter, dashed lines between two LHRs correspond to short consensus
repeats of -0.2 kb . The SCRs extend 0.4 kb beyond the long homologous repeats .
from that in LHR-D by 8 of 18 residues . Peptide 42a differs in 3 of 19 residues
from the homologous sequence at the LHR-B/-C junction and in 13 of 19
residues from that at the LHR-C/-D junction . It is unlikely that peptide 42a is
from the NH2-terminus of LHR-B in which the available derived sequence is
identical to that of the corresponding region of LHR-C (Fig . 4) . The recovery
of amino acids from the first three cycles in the sequencing of these two unique
peptides was 723 ± 321 pmol (mean ± SD) and that of the peptides in Table I
corresponding to sequences in LHR-B, LHR-C, or LHR-D was 1,018 ± 545
pmol . Thus, peptides 56b and 42a are probably not derived from the S allotype
(frequency 0.2) in which a fifth LHRmay be present . The third peptide in Table
II, peptide 9 (1,052 pmol), differs from the homologous sequences of LHR-B,
-C, and -D at five of nine residues, suggesting either that a more divergent
sequence exists in LHR-A, that there is an SCR in the NH2-terminal region of
CR1 that is not part of a long homologous repeat, or that erythrocyteCR 1, from1142 HIGHLY HOMOLOGOUS REPEATS IN CRITryptic peptides from human erythrocyte CRI found in the derived amino acid sequence. The
number ranges in the right-hand column indicate the location of the peptide in the derived amino
acid sequence. Each dash in peptides 66, 28 and49 indicates multiple residues were identified at that
cycle. The dash in peptide 34b indicates no residue was identified at that cycle.
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TABLE I
CR1 Tryptic Peptides Found in the DerivedAmino Acid Sequence
TABLE II
CR1 Tryptic Peptides Not Found in theDerived Amino Acid Sequence
1103
Tryptic peptides not found in the derived amino acid sequence. The peptides are aligned with the
closestmatches from the derivedamino acid sequence, the positions of which are given to the right
ofthe sequence. Spaces were introduced to maximize thealignment. Adash indicates that no residue
was identified at that position. E/T indicates that both E and T were identified at the fifth cycle in
peptide 9.
which the trypticpeptides were derived, contains sequences not found in tonsillar
CR1 .
Each LHR comprises seven 60-70 amino acid SCRs that characterize the
family of C3 and C4 binding proteins (C4bp) (Fig. 5A). Maximal homology
between the 23 SCRs ofCR1 was observed by introducingspaces inthealignment
of the sequences (Fig. 5A). Altogether, 29 of the average 65 residues in each
repeat are conserved. There are six residues that are present in all SCRs: the
four half-cystines that are in similar relative positions suggesting that each may
be involved in a critical disulfide linkage, and the tryptophan and the second
glycine after the second half-cystine (Fig. 5A). Secondary structure analysis of
the sequences between the invariant half-cystines using the algorithm of Chou
and Fasman (32) predicted high probability ,8-turn formationand low probability
a-helix formation. Sequence analysis of two CR1 genomic clones, 2.38 (Fig. 5B)
and 2.46 (data not shown), indicates that SCR-14 (Fig. 5A) is encoded by a single
Peptide
number Aminoacid sequence Residue numbers in the
derived sequence
66 VDFVCDEGFQLKGS-A 330-345
28 GAA S L - - - - QG - W S P EAP 732-749, 1,185-1,202
49 - - - - - - - - - - - - I FC - NP -AIL 805-826, 1,258-1,279
35 CQALNKWE P E L P S C SR 228-243,678-693
41c DKDNFSPGQEVFYSCEPGYDLR 260-281
346 AV -YTCDPHPDRGTSFDLIGESTIR 393-417
44d VCQP P P E I LHG 694-704,1,147-1,157
54d VFELVGEPSIYCTSNDDQVGIWSGPAPQ 152-179,602-629
576 YECRPEYYGRPFS 19-31,469-481
39b LIGHSSAECILSGNAA 85-100
Peptide
number Aminoacid sequence Residue numbers in the
derived sequence
56b LKTQT-ASDFPIGTSLWY
LKTQTNASDFPIGTSLKY 2-19,452-469
PTIPINDFEFPVGTSLNY 905-922
42a CGIL GHCQAPDHFLFAWGY
CGIL GHCQAPDHFLFAKLK 435-453
CELSVRAGHCKTPEQFPFASPT 885-906
9 NSVWE/TGAGH
NGVW S SPAP 425-433, 875-883, 1,328-1,3361104
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FIGURE 6.
￿
Alignment of the consensus sequence of the SCRs ofproteins known to have this
structure . Spaces were introduced to maximize the alignment . A residue is deemed conserved
as in Fig . 5, except for those proteins having only one or two SCRs, in which a residue is
conserved if it is present in at least half of the other proteins . The dashes correspond to
nonconserved positions . The underlined portions ofCR2 and C26 indicate that no sequence
information has been published in this region for these proteins . The boxes indicate the
invariant half-cystines . The number to the right of the sequence represents the number of
SCRs used to generate the consensus sequence . Theprotein abbreviations and references for
the sequence data used to determine the consensus sequences are : (CRI) complement receptor
type 1, (H) factor H (36), (C46p) C4 binding protein (35), (CR2) complement receptor type 2
(28), (Ba) proteolytic fragment of factorB (37), (C2b) proteolytic fragment of C2 (40), (Clr) r
subunit ofC1 (42), (XIIIb) b subunit of factor XIII (44), (02GP1) 02 glycoprotein I (41), (Hap)
haptoglobin (43), (IL-2-R) the IL-2-receptor (34) . Asterisk indicates that incomplete sequence
is available .
exon and that the COOH-terminus of SCR-23 corresponds to the end of an
exon . Thus, the SCRs of CRI may be encoded by separate exons as has been
shown for the SCRs of factor B (33) and of the IL-2-R (34) .
The consensus sequence of the CRI SCRs is compared with the SCRs of the
other members o£ the superfamily having this characteristic structure (Fig . 6) .
These members include not only proteins having C3/C4 binding function, CR2
(28), C4bp (35), factor H (36), factor B (37, 38), and C2 (39, 40), but also the
proteins not known to have this function, the IL-2-R (34), N2-glycoprotein 1 (41),
CIr (42), haptoglobin a chain (43), and factor XIIIb (44) . The half-cystine
residues are invariant in the SCRs of all proteins, except haptoglobin that lacks
the third half-cystine . The tryptophan is also invariant with the exception of the
fifth SCR in 02GP 1 and two of the repeats in factor XIIIb. Other residues that
are conserved but not present in each SCR tend to cluster about thehalf-cystines .
There is only one free thiol group in factor B and C2 (45, 46), and in the SCRs
of 02-glycoprotein I the first half-cystine is disulfide-linked to the third and the
second to the fourth (41) .
--PP+ra----r1---F--B_-VI-~+ 0-NSSP-P-c CRI 23*
V?' -P-I--MOTUR y-K-y -OTI SV W -O-D- 1-4- -O-W --LP - 020P1 4
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In the derived amino acid sequence of CR1 there are 17 potential sites for N-
linked oligosaccharides and all of them are in the extracellular region (Fig. 5A).
Molecular weight differences between CR1 synthesized in the presence and
absence oftunicamycin (23) and analysis ofglucosamine content (47) suggest the
presence of only 6-8 N-linked complex oligosaccharides, indicating that all
potential sites are not used. For example, the asparagine at residue 263 of the
derived amino acid sequence (Fig. 4) was identified in peptide 41c (Table 1),
indicating absence ofglycosylation atthissite. In contrast, the unidentified amino
acid in peptide 34b probably corresponds to a glycosylated asparagine at residue
395.
The only nonrepetitive CR1 sequences identified in the 5.5 kb of cDNA are
located in the COOH-terminal region . A secondary structure analysis of this
region identifies asingle 25-residue putative membrane-spanning segment having
strong hydrophobic character and high potential for a-helix formation (Fig. 4).
This sequence is immediately followed by four positively charged residues, a
characteristic ofmany membrane proteins. The presumed cytoplasmic region of
CR1 comprises 43 residues and contains a six-amino-acid sequence, VHPRTL,
which is homologous to the sequence VRKRTL, a site of protein kinase C
phosphorylation in the EGF receptor and the erbB oncogene product (48, 49).
There are no tyrosine residues in the cytoplasmic region of tonsillar CR1.
Discussion
-80% ofthe primary structure ofthe F allotype of CR1 has been obtained by
sequencing overlapping cDNA clones. The most unusual structural feature of
CR1 observed in this analysis is the presence of tandem, direct LHRs of 450
amino acids, four of which are predicted to occur in the F allotype ofCR1 that
has an estimated polypeptide chain length of 2,000 residues (20, 47). Three of
the LHRs have been cloned and sequenced while evidence for the existence of
the fourth was provided by the analysis of tryptic peptides. Each LHR is
comprised ofseven SCRs which are the basic structural elements ofother C3/C4
binding proteins. The conservation of the four half-cystines per SCR, the
probable involvement of the first and third and the second and fourth half-
cystines in disulfide linkages (41) and the presence ofconservedaminoacids such
as proline, glycine and asparagine which are frequently found in ,6-turns (50)
lead to the proposal that an SCR forms a triple loop structure maintained by
disulfide linkages (Fig. 7). This role for the half-cystine residues is supported by
the finding that mildly trypsin-treated CR1 (47) and factor H (51) migrate as
intact molecules when analyzed by SDS-PAGE under non-reducing conditions
and as multiple tryptic fragments after reduction. This series of tandemly
repeated SCRs is predicted to form an elongated structure (Fig. 7) as has been
proposed for factor H and for each subunit of human C4bp (51-53). Electron
microscopic studies of the subunits of C4bp have indicated dimensions of 300 x
30A (53). As each subunit is composed of eight SCRs (35), an individual SCR is
calculated to be 38 x 30A. Assuming that the SCRs of CR1 have similar
dimensions and that the F allotype has 30 SCRs, the receptor could extend as
much as 1,140A from the cell membrane . Consistent with this prediction ofCR1
structure is the earlier finding that ferritin-labeled antibody bound to CR1 onF .k
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FIGURE 7 . Schematic diagram of the proposed structure of human CRI. The 000H-
terminal cytoplasmic region is on the right side of the lipid bilayer . 30 SCRs are arrayed
linearly on the extracellular side of the plasma membrane . The brackets indicate the LHRs .
The inset is an enlargement of a single SCR to illustrate the triple loop structure .
neutrophils was frequently 500A from the outer leaflet of the plasma membrane
(11) . Such an elongated structure of CR 1 would facilitate the interaction of
receptor-bearing cells with C3b that has covalently bound to relatively inacces-
sible sites within immune complexes and microbial cell surfaces .
The finding that the SCR is the major, and perhaps only, extracytoplasmic
element ofCRI provides structural evidence for a close relationship between the
receptor and factor H and C4bp, two plasma proteins that are exclusively or
predominantly composed of SCRs (35, 36) . CRI was initially isolated as an
erythrocyte membrane protein having factor H-like activity after detergent
solubilization (17), and it was found subsequently to have the regulatory functions
of factor H and C4bp when residing on the plasma membrane (18) . By analysis
of the inheritance of structural polymorphisms ofCR 1, factor H, and C4bp, the
genes encoding these three proteins were shown to be linked (54) and the locus
for this linkage group and for the structurally related receptor, CR2, have been
shown recently by in situ hybridization and by the analysis of somatic cell hybrids
to be on the long arm of chromosome 1, band q32 (55) . Before the present
study, the only evidence for a structural relationship between these proteins was
a significant similarity in their amino acid compositions (26) . Therefore, the
present finding of at least 23 SCRs in CRI constitutes the direct and formal
demonstration of a structural relationship of the receptor with factor H and
C4bp (35, 36), proteins with similar functions, andwith theBa and C2bfragments
of factor B and C2 (37-40), components that form enzymatic complexes with
C3b and C4b, respectively . However, the SCR is also found in several noncom-
plement proteins (33, 41-44) (Fig . 6), indicating that it does not necessarily
represent a C3/C4 binding structure .
Among the proteins having SCRs, CR 1 is unique in having organized this basic
structural and genetic unit into the higher order structural unit of the LHR.
The genetic basis for this organization has not been defined as yet, although
analysis of a 14.5-kb Bam HI fragment ofgenomic DNA that is associated with
expression of the S allotype has suggested that at least one repeating genomic
unit in CR 1 is an extended segment ofDNA containing the exons encoding at
least five SCRs and their flanking introns (25) . These studies have also suggested
that the S allele contains an additional copy of this genomic unit compared with1108
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the number present in the F allele . This observation, combined with a tryptic
peptide mapping study (56) and the present finding that an LHR represents a
peptide of ^-40-50 kD predicts the presence in the S allotype (290 kD) of an
additional LHR relative to the estimate of four LHRs in the F allotype (M,
250,000) .
In addition to providing evidence for duplication events, the sequences of the
LHRs also suggest that conversion events have occurred within the CR 1 gene .
LHR-B and-D are 67% identical to each other throughout their length, whereas
LHR-C is 99% identical to LHR-B in the NH2-terminal four SCRs and 91
identical to LHR-D in the COON-terminal three SCRs. This organization could
not have occurred by a single recombinational event between identical parental
alleles in the origin of this hybrid LHR. Rather, the hybrid LHRmayhave arisen
by gene conversion (57) in which sequences in an LHR-C precursorwere replaced
by sequences present in LHR-B or LHR-D. The near complete identity and
precise alignment ofhomologous sequences in these LHRs (Fig . 4) also may have
been maintained by a mechanism involving gene conversion . Analysis of the
extent of homology between intervening sequences of those segments of the
CRI gene encoding the LHRs should determine whether gene conversion or
selection based on functional constraints have strictly limited sequence diver-
gence .
Although a previous study suggested that CRI is monovalent (58), each LHR
might represent a single C3b/C4b binding domain, which would make the
receptor multivalent and adapted for the binding of complexes bearing multiple
molecules of C3b and C4b. Alternatively, distinct LHRs might be responsible
for binding C3b and C4b, respectively, providing a structural basis for the
combination of factor H and C4bp activities in CRI . Finally, the LHRs of CRI
may represent structural domains that serve to extend CRI from the plasma
membrane, as suggested by the proposed structural model (Fig . 7), and as-yet-
unsequenced SCRs at the NH2-terminal region bind C3b and C4b, as has been
found for factor H (51, 59) .
Activation of protein kinase C by phorbol esters induces phosphorylation of
CRI in neutrophils, monocytes, and eosinophils (60) and the CRI cytoplasmic
domain of 43 amino acids has a sequence that is homologous to a site that is
phosphorylated by protein kinase C in the EGF receptor (48, 49). However, this
cytoplasmic sequence, which was found in three independent clones of the
tonsillar library, is most likely that of B cell CR 1, which is not phosphorylated
after activation of protein kinase C (60) . Determination of the cytoplasmic region
of CR I from myelomonocytic cells, which is phosphorylated when these cells are
treated with phorbol esters, may provide a basis for this differential phosphoryl-
ation of the receptor .
Summary
10 overlapping CRI cDNA clones that span 5 .5 kb were isolated from a
tonsillar library and sequenced in whole or in part . A single long open reading
frame beginning at the 5' end of the clones and extending 4.7 kb downstream
to a stop codon was identified . This sequence represents ^-80% of the estimated
6 kb of coding sequence for the F allotype of CRI . Three tandem, direct, longhomologous repeats (LHRs) of 450 amino acids were identified . Analysis of the
sequences of tryptic peptides provided evidence for a fourth LHR in the F
allotype of CR1 . Amino acid identity between the LHRs ranged from 70%
between the first and third repeats to 99% between theNH2-terminal 250 amino
acids of the first and second repeats . Each LHR comprises seven short consensus
repeats (SCRs) of 60-70 amino acids that resemble the SCRs of other C3/C4
binding proteins, such as complement receptor type 2, factors B and H, C4
binding protein, and C2 . Two additional SCRs join the LHRs to a single
membrane-spanning domain of 25 amino acids ; thus, the F allotype of CR1
probably contains at least 30 SCRs, 23 of which have been sequenced . Each SCR
is predicted to form a triple loop structure in which the four conserved half-
cystines form disulfide linkages . The linear alignment of 30 SCRs as a semi-rigid
structure would extend 1,140.E from the plasma membrane and might facilitate
the interaction of CR 1 with Cab and C4b located within the interstices of
immune complexes and microbial cell walls . The COOH-terminal cytoplasmic
domain of 43 residues contains a six-amino-acid sequence that is homologous to
the sequence in the epidermal growth factor receptor that is phosphorylated by
protein kinase C .
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